Related Experiment Video
Updated: Jan 13, 2026
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3
Andrzej Nowojewski1, Alex Wheal2, William Dott3
1R&D BioPharmaceuticals, AstraZeneca, Cambridge, England, UK andrzej.nowojewski@astrazeneca.com.
Objectives:
To understand participant experience in the INTERLINK-1 clinical trial using the Study Participant Feedback Questionnaire (SPFQ), explore factors associated with participant experience and evaluate the implementation of the SPFQ.
Design:
Phase 3, randomised, double-blind, placebo-controlled, multicentre trial.
Setting:
79 sites in 21 countries from October 2020 to October 2022.
Participants:
371 adults with recurrent/metastatic head and neck squamous cell carcinoma (39% aged >66 years, 69% White and 81% male).
Primary Outcome Measures:
SPFQ administered at enrolment (SPFQ-A), during the trial (SPFQ-B) and at trial completion (SPFQ-C).
Results:
A total of 223, 64 and 93 participants completed the SPFQ-A, SPFQ-B and SPFQ-C, respectively. Early termination of the INTERLINK-1 study limited the number of SPFQ-B and SPFQ-C responses. For all but one question, over 80% of participants selected positive responses, indicating positive experience with regards to enrolment (SPFQ-A), site (SPFQ-B) and overall trial (SPFQ-C). Individually, quality of life, continent and race were significantly associated with participant experience. Small numbers of negative and neutral responses enabled the construction of multiple ordinal regression models and were used to identify unbiased coefficients associated with patient experience. The models showed that males and participants in Asia reported worse experiences in questions regarding trial enrolment (p<0.05). Recent adverse events and higher Eastern Cooperative Oncology Group (ECOG) performance status were significantly negatively associated with trial site satisfaction (B1; OR 0.24, 95% CI 0.06 to 0.96, p<0.05) and site staff-related questions (B5; OR 0.18, 95% CI 0.04 to 0.93, p<0.05), respectively. Indications of acquiescence bias were found, possibly due to SPFQ question design.
Conclusions:
Overall, participants reported positive experiences in the INTERLINK-1 study as evaluated by the SPFQ. Specific aspects of participant experience varied by sex, continent, recent adverse events and ECOG status. Further investigation is required to understand the causes of these findings to develop strategies for improved participant experience. Observations from this study will be used to inform future SPFQ implementation and develop strategies for better, more equitable trial experiences.
Trial Registration Number:
ClinicalTrials.gov: NCT04590963.
More Related Videos
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:27Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
01:20Nursing Process for Patient and Caregiver Teaching III: Evaluation and Documentation
Nurses can use several methods to evaluate patient outcomes. For example, oral questions can assess cognitive learning,...